ReNeuron Group plc (RNUGF)

[georgejjl]

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of
cell-based therapeutics, will webcast the analyst briefing on the day of its
preliminary results, Thursday 11 July 2019.
To listen to the webcast live, please log on to the following web address
approximately 5 minutes before 10.00am BST on the day of results:
https://webcasting.buchanan.uk.com/broadcast/5d011332221579216107d918
A recording of the webcast will later be made available at ReNeuron’s website,
www.reneuron.com.
The analyst briefing will be held at 10.00am BST on 11 July 2019 at the offices of
Buchanan, 107 Cheapside, London EC2V 6DN.
For more information, please contact Buchanan on [e-mail]
or 020 7466 5000.
ENDS
ENQUIRIES:
ReNeuron [phone]
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan (UK) [phone]
Mark Court, Sophie Wills, Tilly Abraham
Argot Partners (US)
Stephanie Marks, Claudia Styslinger
Stifel Nicolaus Europe Limited

[phone]

[phone]
Jonathan Senior, Stewart Wallace, Ben Maddison
(NOMAD and Joint Broker)
Nplus1 Singer Advisory LLP [phone]
Aubrey Powell, Mark Taylor (Joint Broker)
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem
cell technologies to develop ‘off the shelf’ stem cell treatments, without the need
for immunosuppressive drugs. The Company’s lead clinical-stage candidates are in
development for the blindness-causing disease, retinitis pigmentosa, and for
disability as a result of stroke. ReNeuron is also advancing its proprietary exosome
technology platform as a potential delivery system for drugs that would otherwise
be unable to reach their site of action. ReNeuron’s shares are traded on the
London AIM market under the symbol RENE.L. For further information visit
www.reneuron.com.